semaglutide plus cagrilintide nejm Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, has well-established weight-loss benefits. Cagrilintide, a long-acting analogue of the satiety hormone amylin, has shown promise for weight loss in early trials. The potential Cagrilintide and semaglutide together drive

Fatigue should be differentiated from hypoglycemia, which can present with similar symptoms including weakness, shakiness, and difficulty concentrating

You should not change your dosing regimen or stop taking Foundayo as prescribed without discussing with your provider first

Lying down after eating removes this advantage and can worsen reflux, which often coexists with bloating on semaglutide

They will likely wave it through

Management includes: Small, protein-focused meals Avoiding high-fat foods during escalation Adequate hydration Proactive constipation management Slower dose progression What should GPs do if weight loss plateaus